# US 2004/0018196 A1 · Proteins and nucleic acids encoding same

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2004/0018196 A1
- Document ID: US20040018196A1
- Status: Published application
- Kind: A1
- Application number: 10/044,564
- Filed: 2002-01-11
- Published: 2004-01-29
- Earliest claimed: 2001-01-11
- Assignees: CuraGen Corporation
- Inventors: Peter D. Mezes; Luca Rastelli; John L. Herrmann; John R. MacDougall; Haihong Zhong; Stacie J. Casman; Ferenc L. Boldog; Richard A. Shimkets; Linda Gorman; Andrew J. Eisen; Steven K. Spaderna; Corine A.M. Vernet; Constance Berghs; Kimberly A. Spytek; Vincent A. DiPippo; Bryan D. Zerhusen; John A. Peyman; Karen Ellerman; David J. Stone; William M. Grosse; John P. Alsobrook II; Denise M. Lepley; Daniel K. Rieger; Catherine E. Burgess; Shlomit R. Edinger
- Web page: https://patentgrep.com/patent/US20040018196A1

## CPC

- C07K 16/18: against material from animals or humans
- A61K 47/6829: {Bacterial toxins, e.g. diphteria toxins or Pseudomonas exotoxin A}
- A61K 47/6851: {the antibody targeting a determinant of a tumour cell}
- A61K 47/6869: {the tumour determinant being from a cell of the reproductive system: ovaria, uterus, testes, prostate}
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like
- A61P 17/06: Antipsoriatics
- A61P 35/00: Antineoplastic agents
- C07K 14/47: from mammals
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61K 2039/505: {comprising antibodies}
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Disclosed herein are nucleic acid sequences that encode novel polypeptides. Also disclosed are polypeptides encoded by these nucleic acid sequences, and antibodies, which immunospecifically-bind to the polypeptide, as well as derivatives, variants, mutants, or fragments of the aforementioned polypeptide, polynucleotide, or antibody. The invention further discloses therapeutic, diagnostic and research methods for diagnosis, treatment, and prevention of disorders involving any one of these novel human nucleic acids and proteins.

## Claims

### Claim 1

A method of treating or delaying the onset of an angiogenic-associated disorder, said method comprising administering to a subject in need thereof an antibody to the polypeptide of SEC1 in an amount sufficient to treat or prevent said angiogenic-associated disorder in said subject.

### Claim 2 (depends on 1)

The method of claim 1 wherein the subject is a human.

### Claim 3 (depends on 1)

The method of claim 1 wherein the angiogenic-associated disorder is selected from the group consisting of a cancer, cardiovascular disease, psoriasis, wound healing, and stroke.

### Claim 4 (depends on 1)

The method of claim 1 wherein the angiogenic-associated disorder comprises endothelial cell adhesion to an extracellular matrix protein.

### Claim 5 (depends on 4)

The method of claim 4 wherein the extracellular matrix protein is fibronectin or vitronectin.

### Claim 6

A method for determining the presence of or predisposition to a disease associated with altered levels of SEC1 in a first mammalian subject, said method comprising:
(a) providing a protein sample from said first mammalian subject;
(b) providing a control protein sample from a second mammalian subject known not to have or be predisposed to said disease;
(c) measuring the amount of SEC1 polypeptide in said subject sample; and
(d) comparing the amount of SEC1 polypeptide in said subject protein sample to the amount of SEC1 polypeptide in said control protein sample,
wherein an alteration in the expression level of the SEC1 polypeptide in the first subject sample as compared to the control sample indicates the presence or predisposition to said disease.

### Claim 7

A method for determining the presence of or predisposition to a disease associated with altered levels of the nucleic acid of SEC1 in a first mammalian subject, said method comprising:
(a) providing a nucleic acid sample from said first mammalian subject;
(b) providing a control nucleic acid sample from a second mammalian subject known not to have or be predisposed to said disease;
(c) measuring the amount of SEC1 nucleic acid in said subject sample; and
(d) comparing the amount of SEC1 nucleic acid in said subject nucleic acid sample to the amount of SEC1 nucleic acid in said control nucleic acid sample,
wherein an alteration in the expression level of the SEC1 nucleic acid in the first subject sample as compared to the control sample indicates the presence or predisposition to said disease.

### Claim 8

A method of treating a pathological state in a mammal, the method comprising administering to the mammal a SEC1 polypeptide in an amount sufficient to alleviate the pathological state, wherein the polypeptide has an amino acid sequence at least 95% identical to the SEC1 polypeptide, or a biologically active fragment thereof.

### Claim 9

A method of treating a pathological state in a mammal, the method comprising administering to the mammal an antibody to a SEC1 polypeptide in an amount sufficient to alleviate the pathological state.

### Claim 10 (depends on 8)

The method of claim 8 wherein the pathological state is selected from the group consisting of a cancer, cardiovascular disease, psoriasis, wound healing, and stroke.

### Claim 11 (depends on 8)

The method of claim 8 wherein the pathological state comprises endothelial cell adhesion to an extracellular matrix protein.

### Claim 12 (depends on 11)

The method of claim 11 wherein the extracellular matrix protein is fibronectin or vitronectin.

### Claim 13

A method of treating or delaying the onset of a disorder, said method comprising administering to a subject in need thereof an antibody to the polypeptide of SEC1, SEC2, SEC3, SEC4, SEC5, SEC6, SEC7, SEC8, SEC9, SEC10, SEC11, or SEC12 in an amount sufficient to treat or prevent said disorder in said subject

### Claim 14

A method of treating a pathological state in a mammal, the method comprising administering to the mammal a SEC1, SEC2, SEC3, SEC4, SEC5, SEC6, SEC7, SEC8, SEC9, SEC10, SEC11, or SEC12 polypeptide in an amount sufficient to alleviate the pathological state, wherein the polypeptide has an amino acid sequence at least 95% identical to the SEC1, SEC2, SEC3, SEC4, SEC5, SEC6, SEC7, SEC8, SEC9, SEC10, SEC11, or SEC12 polypeptide, or a biologically active fragment thereof.

### Claim 15

A method for determining the presence of or predisposition to a disease associated with altered levels of SEC1, SEC2, SEC3, SEC4, SEC5, SEC6, SEC7, SEC8, SEC9, SEC10, SEC11, or SEC12 in a first mammalian subject, said method comprising
(a) Providing a sample from said first mammalian subject;
(b) Providing a control sample from a second mammalian subject known not to have or be predisposed to said disease;
(c) Measuring the amount of SEC1, SEC2, SEC3, SEC4, SEC5, SEC6, SEC7, SEC8, SEC9, SEC10, SEC11, or SEC12 in said subject sample; and
(d) Comparing the amount of SEC1, SEC2, SEC3, SEC4, SEC5, SEC6, SEC7, SEC8, SEC9, SEC10, SEC11, or SEC12 in said subject protein sample to the amount of SEC1, SEC2, SEC3, SEC4, SEC5, SEC6, SEC7, SEC8, SEC9, SEC10, SEC11, or SEC12 in said control sample,
wherein an alteration in the expression level of the SEC1, SEC2, SEC3, SEC4, SEC5, SEC6, SEC7, SEC8, SEC9, SEC10, SEC11, or SEC12 in the first subject sample as compared to the control sample indicates the presence or predisposition to said disease.

### Claim 16

An isolated polypeptide comprising an amino acid sequence selected from the group consisting of:
(a) a mature form of an amino acid sequence selected from the group consisting of SEQ ID NOS:26,28, 30, 32, 34, 36, 38 and 40;
(b) a variant of a mature form of an amino acid sequence selected from the group consisting of SEQ ID NOS:26, 28, 30, 32, 34, 36, 38 and 40, wherein one or more amino acid residues in said variant differs from the amino acid sequence of said mature form, provided that said variant differs in no more than 15% of the amino acid residues from the amino acid sequence of said mature form;
(c) an amino acid sequence selected from the group consisting SEQ ID NOS:26, 28, 30, 32, 34, 36, 38and40;and
(d) a variant of an amino acid sequence selected from the group consisting of SEQ ID NOS:26, 28, 30, 32, 34, 36, 38 and 40, wherein one or more amino acid residues in said variant differs from the amino acid sequence of said mature form, provided that said variant differs in no more than 15% of amino acid residues from said amino acid sequence.

### Claim 17 (depends on 16)

The polypeptide of claim 16, wherein said polypeptide comprises the amino acid sequence of a naturally-occurring allelic variant of an amino acid sequence selected from the group consisting SEQ ID NOS:26, 28, 30, 32, 34, 36, 38 and 40.

### Claim 18 (depends on 16)

The polypeptide of claim 16, wherein said allelic variant comprises an amino acid sequence that is the translation of a nucleic acid sequence differing by a single nucleotide from a nucleic acid sequence selected from the group consisting of SEQ ID NOS:25, 27, 29, 31, 33, 35, 37 and 39.

### Claim 19 (depends on 16)

The polypeptide of claim 16, wherein the amino acid sequence of said variant comprises a conservative amino acid substitution.

### Claim 20

An isolated nucleic acid molecule comprising a nucleic acid sequence encoding a polypeptide comprising an amino acid sequence selected from the group consisting of:
(a) a mature form of an amino acid sequence selected from the group consisting of SEQ ID NOS:26, 28, 30, 32, 34, 36, 38 and 40;
(b) a variant of a mature form of an amino acid sequence selected from the group consisting of SEQ ID NOS:26, 28, 30, 32, 34, 36, 38 and 40, wherein one or more amino acid residues in said variant differs from the amino acid sequence of said mature form, provided that said variant differs in no more than 15% of the amino acid residues from the amino acid sequence of said mature form;
(c) an amino acid sequence selected from the group consisting of SEQ ID NOS:26, 28, 30, 32, 34, 36, 38 and 40;
(d) a variant of an amino acid sequence selected from the group consisting SEQ ID NOS:26, 28, 30, 32, 34 36.38 and 40, wherein one or more amino acid residues in said variant differs from the amino acid sequence of said mature form, provided that said variant differs in no more than 15% of amino acid residues from said amino acid sequence;
(e) a nucleic acid fragment encoding at least a portion of a polypeptide comprising an amino acid sequence chosen from the group consisting of SEQ ID NOS:26, 28, 30, 32, 34, 36, 38 and 40, or a variant of said polypeptide, wherein one or more amino acid residues in said variant differs from the amino acid sequence of said mature form, provided that said variant differs in no more than 15% of amino acid residues from said amino acid sequence; and
(f) a nucleic acid molecule comprising the complement of (a), (b), (c), (d) or (e).

### Claim 21 (depends on 20)

The nucleic acid molecule of claim 20, wherein the nucleic acid molecule comprises the nucleotide sequence of a naturally-occurring allelic nucleic acid variant.

### Claim 22 (depends on 20)

The nucleic acid molecule of claim 20, wherein the nucleic acid molecule encodes a polypeptide comprising the amino acid sequence of a naturally-occurring polypeptide variant.

### Claim 23 (depends on 20)

The nucleic acid molecule of claim 20, wherein the nucleic acid molecule differs by a single nucleotide from a nucleic acid sequence selected from the group consisting of SEQ ID NOS:25, 27, 29, 31, 33, 35, 37 and 39.

### Claim 24 (depends on 20)

The nucleic acid molecule of claim 20, wherein said nucleic acid molecule comprises a nucleotide sequence selected from the group consisting of:
(a) a nucleotide sequence selected from the group consisting of SEQ ID NOS:25, 27, 29, 31, 33, 35, 37 and 39;
(b) a nucleotide sequence differing by one or more nucleotides from a nucleotide sequence selected from the group consisting of SEQ ID NOS:25, 27, 29, 31, 33, 35, 37 and 39, provided that no more than 20% of the nucleotides differ from said nucleotide sequence;
(c) a nucleic acid fragment of (a); and
(d) a nucleic acid fragment of (b).

### Claim 25 (depends on 20)

The nucleic acid molecule of claim 20, wherein said nucleic acid molecule hybridizes under stringent conditions to a nucleotide sequence chosen from the group consisting SEQ ID NOS:25, 27, 29, 31, 33, 35, 37 and 39, or a complement of said nucleotide sequence.

### Claim 26 (depends on 20)

The nucleic acid molecule of claim 20, wherein the nucleic acid molecule comprises a nucleotide sequence selected from the group consisting of:
(a) a first nucleotide sequence comprising a coding sequence differing by one or more nucleotide sequences from a coding sequence encoding said amino acid sequence, provided that no more than 20% of the nucleotides in the coding sequence in said first nucleotide sequence differ from said coding sequence;
(b) an isolated second polynucleotide that is a complement of the first polynucleotide; and
(c) a nucleic acid fragment of (a) or (b).

### Claim 27 (depends on 26)

A vector comprising the nucleic acid molecule of claim 26.

### Claim 28 (depends on 27)

The vector of claim 27, further comprising a promoter operably-linked to said nucleic acid molecule.

### Claim 29 (depends on 27)

A cell comprising the vector of claim 27.

### Claim 30 (depends on 16)

An antibody that binds immunospecifically to the polypeptide of claim 16.

### Claim 31 (depends on 30)

The antibody of claim 30, wherein said antibody is a monoclonal antibody.

### Claim 32 (depends on 30)

The antibody of claim 30, wherein the antibody is a humanized antibody.

### Claim 33 (depends on 16)

A method for determining the presence or amount of the polypeptide of claim 16 in a sample, the method comprising:
(a) providing the sample;
(b) contacting the sample with an antibody that binds immunospecifically to the polypeptide; and
(c) determining the presence or amount of antibody bound to said polypeptide, thereby determining the presence or amount of polypeptide in said sample.

### Claim 34 (depends on 16)

A method for determining the presence or amount of the nucleic acid molecule of claim 16 in a sample, the method comprising:
(a) providing the sample;
(b) contacting the sample with a probe that binds to said nucleic acid molecule; and
(c) determining the presence or amount of the probe bound to said nucleic acid molecule,
thereby determining the presence or amount of the nucleic acid molecule in said sample.

### Claim 35 (depends on 34)

The method of claim 34 wherein presence or amount of the nucleic acid molecule is used as a marker for cell or tissue type.

### Claim 36 (depends on 35)

The method of claim 35 wherein the cell or tissue type is cancerous.

### Claim 37 (depends on 16)

A method of identifying an agent that binds to a polypeptide of claim 16, the method comprising:
(a) contacting said polypeptide with said agent; and
(b) determining whether said agent binds to said polypeptide.

### Claim 38 (depends on 37)

The method of claim 37 wherein the agent is a cellular receptor or a downstream effector.

### Claim 39 (depends on 16)

A method for identifying an agent that modulates the expression or activity of the polypeptide of claim 16, the method comprising:
(a) providing a cell expressing said polypeptide;
(b) contacting the cell with said agent, and
(c) determining whether the agent modulates expression or activity of said polypeptide,
whereby an alteration in expression or activity of said peptide indicates said agent modulates expression or activity of said polypeptide.

### Claim 40 (depends on 16)

A method for modulating the activity of the polypeptide of claim 16, the method comprising contacting a cell sample expressing the polypeptide of said claim with a compound that binds to said polypeptide in an amount sufficient to modulate the activity of the polypeptide.

### Claim 41 (depends on 16)

A method of treating or preventing a NOVX-associated disorder, said method comprising administering to a subject in which such treatment or prevention is desired the polypeptide of claim 16 in an amount sufficient to treat or prevent said NOVX-associated disorder in said subject.

### Claim 42 (depends on 41)

The method of claim 41 wherein the disorder is selected from the group consisting of cardiomyopathy and atherosclerosis.

### Claim 43 (depends on 41)

The method of claim 41 wherein the disorder is related to cell signal processing and metabolic pathway modulation.

### Claim 44 (depends on 41)

The method of claim 41, wherein said subject is a human.

### Claim 45 (depends on 20)

A method of treating or preventing a NOVX-associated disorder, said method comprising administering to a subject in which such treatment or prevention is desired the nucleic acid of claim 20 in an amount sufficient to treat or prevent said NOVX-associated disorder in said subject.

### Claim 46 (depends on 45)

The method of claim 45 wherein the disorder is selected from the group consisting of cardiomyopathy and atherosclerosis.

### Claim 47 (depends on 45)

The method of claim 45 wherein the disorder is related to cell signal processing and metabolic pathway modulation.

### Claim 48 (depends on 45)

The method of claim 45, wherein said subject is a human.

### Claim 49 (depends on 30)

A method of treating or preventing a NOVX-associated disorder, said method comprising administering to a subject in which such treatment or prevention is desired the antibody of claim 30 in an amount sufficient to treat or prevent said NOVX-associated disorder in said subject.

### Claim 50 (depends on 49)

The method of claim 49 wherein the disorder is diabetes.

### Claim 51 (depends on 49)

The method of claim 49 wherein the disorder is related to cell signal processing and metabolic pathway modulation.

### Claim 52 (depends on 49)

The method of claim 49, wherein the subject is a human.

### Claim 53 (depends on 16)

A pharmaceutical composition comprising the polypeptide of claim 16 and a pharmaceutically-acceptable carrier.

### Claim 54 (depends on 20)

A pharmaceutical composition comprising the nucleic acid molecule of claim 20 and a pharmaceutically-acceptable carrier.

### Claim 55 (depends on 30)

A pharmaceutical composition comprising the antibody of claim 30 and a pharmaceutically-acceptable carrier.

### Claim 56 (depends on 53)

A kit comprising in one or more containers, the pharmaceutical composition of claim 53.

### Claim 57 (depends on 54)

A kit comprising in one or more containers, the pharmaceutical composition of claim 54.

### Claim 58 (depends on 55)

A kit comprising in one or more containers, the pharmaceutical composition of claim 55.

### Claim 59 (depends on 16)

A method for determining the presence of or predisposition to a disease associated with altered levels of the polypeptide of claim 16 in a first mammalian subject, the method comprising:
(a) measuring the level of expression of the polypeptide in a sample from the first mammalian subject; and
(b) comparing the amount of said polypeptide in the sample of step (a) to the amount of the polypeptide present in a control sample from a second mammalian subject known not to have, or not to be predisposed to, said disease;
wherein an alteration in the expression level of the polypeptide in the first subject as compared to the control sample indicates the presence of or predisposition to said disease.

### Claim 60 (depends on 59)

The method of claim 59 wherein the predisposition is to a cancer.

### Claim 61 (depends on 20)

A method for determining the presence of or predisposition to a disease associated with altered levels of the nucleic acid molecule of claim 20 in a first mammalian subject, the method comprising:
(a) measuring the amount of the nucleic acid in a sample from the first mammalian subject; and
(b) comparing the amount of said nucleic acid in the sample of step (a) to the amount of the nucleic acid present in a control sample from a second mammalian subject known not to have or not be predisposed to, the disease;
wherein an alteration in the level of the nucleic acid in the first subject as compared to the control sample indicates the presence of or predisposition to the disease.

### Claim 62 (depends on 61)

The method of claim 61 wherein the predisposition is to a cancer.

### Claim 63

A method of treating a pathological state in a mammal, the method comprising administering to the mammal a polypeptide in an amount that is sufficient to alleviate the pathological state, wherein the polypeptide is a polypeptide having an amino acid sequence at least 95% identical to a polypeptide comprising an amino acid sequence of at least one of SEQ ID NOS: 26, 28, 30, 32, 34, 36, 38 and 40, or a biologically active fragment thereof.

### Claim 64 (depends on 30)

A method of treating a pathological state in a mammal, the method comprising administering to the mammal the antibody of claim 30 in an amount sufficient to alleviate the pathological state.
